[{"orgOrder":0,"company":"McGill University","sponsor":"Weizmann Institute of Science | Apotex Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Enoxacin","moa":"Topoisomerase IV | DNA gyrase","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"McGill University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"McGill University \/ Weizmann Institute of Science | Apotex Inc","highestDevelopmentStatusID":"7","companyTruncated":"McGill University \/ Weizmann Institute of Science | Apotex Inc"}]

Find Clinical Drug Pipeline Developments & Deals for Enoxacin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Coatings Trends
                          Not Confirmed
                          Coatings Trends
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 12, 2021

                          Lead Product(s) : Enoxacin

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Weizmann Institute of Science | Apotex Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank